Genovac
Business Services · North Dakota, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1810 Ndsu Research Cir N Ste B, Fargo, N...Phone Number
(701) 551-2770Website
www.genovac.comRevenue
$26.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Genovac
Genovac is a contract research organization that offers the world's most advanced antibody discovery solutions. Its immunization technologies, combined with advanced hybridoma and the Berkeley Lights Beacon platform, enable success against the most challenging targets. In addition to its headquarters and labs in Fargo, Genovac operates a second scientific and production facility in Freiburg, Germany. Since its founding in 1999, Genovac has completed more than 3,500 projects, providing antibodies to clients in North America, Europe, Australia and Asia that have been developed into clinical and commercial drugs. Genovac also has completed more than 25 client and internal COVID-19 campaigns and has developed two antibodies that successfully neutralize the United Kingdom, Brazilian and South African mutations.Explore more
Genovac Org Chart
BT
Management Vice President, Global Quality
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genovac your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Genovac has recently received funding, and reach out quickly before it becomes old news!
Genovac, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Genovac has new funding data
Click to see if Genovac had a recent Job posting/layoffs
Earning: See what the market has to say on Genovac recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Genovac is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Genovac
Product Launch: Get notified when Genovac launches new products
Recommended Actions
Find VP level buyers at Genovac
Find 2 more new buyers
Compare Similar Companies to Genovac
Compare insights from companies similar to Genovac, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Genovac is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Genovac is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Genovac.
Genovac Tech Stack
A closer look at the technologies used by Genovac
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Event
will be attending the 15th Annual PEGS Europe 2023 conference as an exhibitor. The event will occur from November 14 to November 16, 2023.
Events
Event
Events
Genovac News & Media
Public-Private Collaboration Takes Aim at Hard-to-Target Cancers
Genovac and North Dakota State University Partner to Develop Novel Therapeutics for Hard-to-Treat Cancers FARGO, NORTH DAKOTA, UNITED STATES OF AMERICA, March 13, 2023 /EINPresswire.com/ -- Public-Private Collaboration Takes Aim at Hard-to-Target …Genovac further enhances its antibody discovery services with the ENPICOM IGX Platform
Genovac will use ENPICOM’s world-leading cloud platform to accelerate and improve antibody discovery and early de-risking of development for clients FARGO, NORTH DAKOTA, U.S.A., May 2, 2022 /EINPresswire.com/ -- Genovac, a leading contract research and …Genovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services
FARGO, North Dakota & SALT LAKE CITY, Utah--(BUSINESS WIRE)--Genovac, a leading contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments, and Carterra, Inc., the world leader in label-free high-throughput antibody screening and characterization, today announced that Genovac has acquired Carterra’s LSA platform for use in its discovery services. Genovac, previously a part of AldevronGenovac to Present Innovations in Antibody Discovery Against Challenging Targets at Festival of Biologics in San Diego
FARGO, NORTH DAKOTA, U.S., March 7, 2022 /EINPresswire.com/ -- Genovac, a contract research and manufacturing organization specializing in antibody discovery against challenging targets, will be presenting at this year’s Festival of Biologics conference …
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Genovac
Sign Up For FreeTo access detailed company insights
Genovac is a contract research organization that offers the world's most advanced antibody discovery solutions. Its immunization technologies, combined with advanced hybridoma and the Berkeley Lights Beacon platform, enable success against the most challenging targets. In addition to its headquarters and labs in Fargo, Genovac operates a second sci... Read More
